NCT00406107 - Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

April 30, 2008

Conditions

Branch Retinal Vein Occlusion

Interventions

DRUG

pegaptanib sodium (Macugen)

Subjects were randomized 3:1 to intravitreous injections of pegaptanib 0.3mg or 1mg at baseline and at weeks 6 and 12 with subsequent injections at 6-week intervals at investigator discretion until week 48.

Trial Locations (3)

21740

Cumberland Valley Retina Center, Hagerstown

29169

Palmetto Retina Center, West Columbia

90095

Jules Stein Eye Institute, Los Angeles